Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Anaplastic Lymphoma Kinase (ALK)- Positive Tumors”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Large-scale testing (Phase 3)Study completedNCT02737501
What this trial is testing

ALTA-1L Study: A Study of Brigatinib Versus Crizotinib in Anaplastic Lymphoma Kinase Positive (ALK+) Advanced Non-small Cell Lung Cancer (NSCLC) Participants

Who this might be right for
Non-small Cell Lung CancerLung CancerAdvanced Malignancies+1 more
Ariad Pharmaceuticals 275
Early research (Phase 1)Active Not RecruitingNCT02393625
What this trial is testing

Study of Safety and Efficacy of Ceritinib in Combination With Nivolumab in Patients With ALK-positive Non-small Cell Lung Cancer

Who this might be right for
ALK-positive NSCLC
Novartis Pharmaceuticals 57
Testing effectiveness (Phase 2)Study completedNCT04318938
What this trial is testing

Advancing Brigatinib Properties in ALK+ NSCLC Patients by Deep Phenotyping

Who this might be right for
NSCLC
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest 118
Early research (Phase 1)Looking for participantsNCT07140016
What this trial is testing

Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)

Who this might be right for
Non-small Cell Lung Cancer (NSCLC)Anaplastic Lymphoma Kinase (ALK) Positive
Astellas Pharma Global Development, Inc. 40
Testing effectiveness (Phase 2)Study completedNCT04042558
What this trial is testing

A Study Evaluating Platinum-Pemetrexed-Atezolizumab (+/-Bevacizumab) for Patients With Stage IIIB/IV Non-squamous Non-small Cell Lung Cancer With EGFR Mutations, ALK Rearrangement or ROS1 Fusion Progressing After Targeted Therapies

Who this might be right for
NSCLC Stage IIIBNSCLC Stage IVEGFR Gene Mutation+2 more
Centre Francois Baclesse 150
Not applicableNo Longer AvailableNCT02784158
What this trial is testing

An Expanded Access Study of Brigatinib for Patients With ALK-positive Advanced Non-Small Cell Lung Cancer

Who this might be right for
Non-small Cell Lung CancerLung CancerAdvanced Malignancies+1 more
Ariad Pharmaceuticals
Large-scale testing (Phase 3)Looking for participantsNCT05770037
What this trial is testing

DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Paediatric and Teenage/Young Adult Patients With ALK Positive Cancers

Who this might be right for
Haematological MalignancyMalignant NeoplasmLymphoproliferative Disorders+8 more
Cancer Research UK 30
Large-scale testing (Phase 3)Study completedNCT01639001
What this trial is testing

Crizotinib Versus Chemotherapy In Previously Untreated ALK Positive East Asian Non-Small Cell Lung Cancer Patients

Who this might be right for
NSCLC (Non-small Cell Lung Cancer)
Pfizer 207
Testing effectiveness (Phase 2)Study completedNCT03779191
What this trial is testing

Alectinib in Combination With Bevacizumab in ALK Positive NSCLC

Who this might be right for
ALK Gene Rearrangement PositiveNon-Squamous Non-Small Cell Neoplasm of Lung
Instituto Nacional de Cancerologia de Mexico 41
Large-scale testing (Phase 3)UnknownNCT05341583
What this trial is testing

Ensartinib as Adjuvant Treatment in Anaplastic Lymphoma Kinase (ALK) Positive Non-small Cell Lung Cancer

Who this might be right for
Non-small Cell Lung Cancer
Betta Pharmaceuticals Co., Ltd. 202
Large-scale testing (Phase 3)Not Yet RecruitingNCT06254599
What this trial is testing

SY-3505 Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC

Who this might be right for
Non-small Cell Lung Cancer
Shouyao Holdings (Beijing) Co. LTD 255
Not applicableStudy completedNCT04887519
What this trial is testing

Brigatinib to Treat Adults With Anaplastic Lymphoma Kinase (ALK) Positive Metastatic Non Small Cell Lung Cancer (NSCLC)

Who this might be right for
Carcinoma, Non-Small-Cell LungAnaplastic Lymphoma Kinase
Takeda 39
Early research (Phase 1)Study completedNCT01284192
What this trial is testing

Study of an Investigational Drug, ASP3026, in Patients With Advanced Malignancies (Solid Tumors and B-Cell Lymphoma)

Who this might be right for
Advanced MalignanciesPositive for Anaplastic Lymphoma KinasePositive for Proto-Oncogene Tyrosine-Protein Kinase ROS+2 more
Astellas Pharma Inc 46
Not applicableStudy completedNCT03271554
What this trial is testing

Treatment Registry of Alectinib in Anaplastic Lymphoma Kinase (ALK)-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer in Korea

Who this might be right for
Non-Small Cell Lung Cancer
Hoffmann-La Roche 355
Testing effectiveness (Phase 2)UnknownNCT04989322
What this trial is testing

Pembrolizumab, Lenvatinib and Chemotherapy After TKIs in NSCLC

Who this might be right for
NsclcEGFR Activating MutationEGF-R Positive Non-Small Cell Lung Cancer+3 more
Dr Joanne CHIU 46
Large-scale testing (Phase 3)Study completedNCT02838420
What this trial is testing

Evaluate and Compare the Efficacy and Safety of Alectinib Versus Crizotinib and to Evaluate the Pharmacokinetics of Alectinib in Asian Participants With Treatment-Naive Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC)

Who this might be right for
Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer
Hoffmann-La Roche 187
Testing effectiveness (Phase 2)Study completedNCT03535740
What this trial is testing

Brigatinib in Participants With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib

Who this might be right for
ALK-positive Advanced NSCLC
Ariad Pharmaceuticals 103
Testing effectiveness (Phase 2)WithdrawnNCT01500824
What this trial is testing

A Clinical Study Testing The Safety And Efficacy Of Crizotinib In East Asian Patients With Anaplastic Lymphoma Kinase (ALK) Positive Advanced Non-Small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung Cancer
Pfizer
Testing effectiveness (Phase 2)Ended earlyNCT04644315
What this trial is testing

A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors

Who this might be right for
NeoplasmsColorectal NeoplasmsMelanoma+25 more
Hoffmann-La Roche 1
Testing effectiveness (Phase 2)WithdrawnNCT05948462
What this trial is testing

Lorlatinib in Combination With Chemotherapy in Participants With Metastatic Anaplastic Lymphoma Kinase Positive (ALK+) Non-small Cell Lung Cancer (NSCLC) Who Progressed on Single-agent Lorlatinib

Who this might be right for
Lung CancerNon-small Cell Lung Cancer
SCRI Development Innovations, LLC
Next Page